The importance of CD30 in clinical care

NCCN

NCCN guidelines® on CD30 testing*

The NCCN Guidelines recommend CD30 testing for the differential diagnosis of Hodgkin and certain types of non-Hodgkin lymphoma (NHL).

CD30 screening is considered essential for immunophenotyping and differential diagnosis of certain T-cell lymphomas and is recommended as part of the immunohistochemistry panel in Hodgkin lymphoma.1,2

Learn more about CD30 in the NCCN Guidelines Learn more about CD30 in the NCCN Guidelines

Diagnosis

The clinical relevance of CD30

Screening for CD30 can assist with the differential diagnosis of CD30-expressing tumors.1,2

Appropriate management of patients with lymphoma depends on an accurate diagnosis.3 Immunophenotyping improves diagnostic accuracy by 10% to 45% for a number of major lymphoma subtypes.4

Learn more about CD30 in lymphoma diagnosis Learn more about CD30 in lymphoma diagnosis

Prognosis

The prognostic value of CD30

In several types of NHL, levels of CD30 expression correlate with overall survival (OS).5,6,7

Five-year OS for peripheral T-cell lymphoma, not otherwise specified is 32%, but if ≥80% of the cells are CD30-positive, OS is only 19%. Determining CD30 expression can therefore facilitate a risk-adapted approach to treatment.5,8

Learn more about CD30 in NHL prognosis Learn more about CD30 in NHL prognosis

References

  1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Hodgkin Lymphoma (Version 2.2013). © 2013 National Comprehensive Cancer Network, Inc. Available at NCCN.org. Accessed September 24, 2013.
  2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Non-Hodgkin’s Lymphomas (Version 2.2013). © 2013 National Comprehensive Cancer Network, Inc. Available at NCCN.org. Accessed September 24, 2013.
  3. Matasar MJ, Shi W, Silberstien J, et al. Expert second-opinion pathology review of lymphoma in the era of the World Health Organization classification. Ann Oncol. 2012;23(1):159-166.
  4. The Non-Hodgkin’s Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin’s Lymphoma. Blood. 1997;89(11):3909-3918.
  5. Savage KJ, Harris NL, Vose JM, et al; for International Peripheral T-Cell Lymphoma Project. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111(12):5496-5504.
  6. Camacho FI, Bellas C, Corbacho C, et al. Improved demonstration of immunohistochemical prognostic markers for survival in follicular lymphoma cells. Mod Pathol. 2011;24(5):698-707.
  7. Hu S, Xu-Monette ZY, Balasubramanyam A, et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program study. Blood. 2013;121(14):2715-2724.
  8. Kadin ME, Carpenter C. Systemic and primary cutaneous anaplastic large cell lymphomas. Semin Hematol. 2003;40(3):244-256.

*Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Hodgkin’s Lymphomas V.2.2013 and Hodgkin Lymphoma V.2.2013. © National Comprehensive Cancer Network, Inc 2013. All rights reserved. Accessed September 24, 2013. To view the most recent and complete version of the guideline, go online to www.nccn.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc.